Provided by Tiger Fintech (Singapore) Pte. Ltd.

Regenxbio

9.12
+0.19002.13%
Volume:423.34K
Turnover:3.90M
Market Cap:460.69M
PE:-2.66
High:9.43
Open:8.75
Low:8.75
Close:8.93
52wk High:13.48
52wk Low:5.04
Shares:50.51M
Float Shares:41.42M
Volume Ratio:0.74
T/O Rate:1.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4333
EPS(LYR):-4.5871
ROE:-62.49%
ROA:-17.88%
PB:2.16
PE(LYR):-1.99

Loading ...

REGENXBIO Inc. to Participate in Wells Fargo Healthcare Conference in Boston

Reuters
·
Aug 28

Goldman Sachs Sticks to Their Hold Rating for RegenXBio (RGNX)

TIPRANKS
·
Aug 20

REGENXBIO Price Target Maintained With a $34.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 19

BRIEF-Regenxbio Announces FDA Review Extension Of BLA For RGX-121 To Treat Patients With MPS II

Reuters
·
Aug 19

BUZZ-Regenxbio falls after FDA extends review of genetic disorder therapy

Reuters
·
Aug 19

Regenxbio announces FDA review extension for RGX-121 BLA

TIPRANKS
·
Aug 19

REGENXBIO Inc. Announces FDA Extension of Review Timeline for RGX-121 BLA to February 2026 for Hunter Syndrome Therapy

Reuters
·
Aug 19

Regenxbio Inc - Pdufa Date Extended to February 8, 2026

THOMSON REUTERS
·
Aug 19

Regenxbio Announces FDA Review Extension of Bla for Rgx-121 to Treat Patients With Mps Ii

THOMSON REUTERS
·
Aug 19

Leerink Partners Reaffirms Their Buy Rating on RegenXBio (RGNX)

TIPRANKS
·
Aug 12

Analysts Offer Insights on Healthcare Companies: Myomo (MYO), Quoin Pharmaceuticals (QNRX) and RegenXBio (RGNX)

TIPRANKS
·
Aug 08

REGENXBIO Is Maintained at Overweight by Barclays

Dow Jones
·
Aug 08

RBC Cuts Price Target on REGENXBIO to $17 From $21, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Aug 08

REGENXBIO Reports Q2 2025 Financial Results and Progress

TIPRANKS
·
Aug 08

Raymond James Remains a Buy on RegenXBio (RGNX)

TIPRANKS
·
Aug 08

Regenxbio Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 08

BRIEF-Regenxbio Inc - Phase Iib/Iii Trial To Be Initiated For Diabetic Retinopathy

Reuters
·
Aug 07

Regenxbio Q2 EPS $(1.38) Misses $(1.10) Estimate, Sales $21.36M Miss $28.11M Estimate

Benzinga
·
Aug 07

Regenxbio Inc - Phase Iib/Iii Trial to Be Initiated for Diabetic Retinopathy

THOMSON REUTERS
·
Aug 07

Regenxbio Inc - to Receive $100 Mln Upon First Subject Dosed

THOMSON REUTERS
·
Aug 07